Gallegos-Hernández F, Tanis PJ, Nieweg OE, Duerloo E, Valdés-Olmos R, Rutgers EJT, Kroon BB

Language: Spanish
References: 20
Page: 421-426
PDF size: 70.76 Kb.

ABSTRACT

Introduction: Intratumoral injection of nanocolloid for lymphatic mapping enables therapeutic excision of clinically occult breast cancer with the aid of a gamma ray detection probe. Objective:The aim of this study was to determine the success rate of radioguided tumor excision in addition to a guide wire and to identify factors predicting clear margins. Material and methods: Sixty five consecutive patients with invasive occult breast cancer underwent radioguided tumor excision after intratumoral injection of ⁹⁹ mTc-nanocolloid guided by ultrasound or stereotaxis. A localization wire was inserted; subsequently scintigraphy was performed (group 1). Results were compared with retrospective data from 67 consecutive patients who underwent therapeutic wire-directed excision alone (group 2). Factors predicting clear margin (>1 mm) were determined in a logistic regression model. Results: Adequate margins were obtained in 83 (group 1) and 64% (group 2; p = 0.014) respectively. The invasive component was performed in 4 and 14 patients, respectively. Factors predictive of clear margins were decreasing pathologic tumor diameter (p = 0.035), increasing weight of specimen (p = 0.046), absence of micro-calcifications (p = 0.004), and absence of carcinoma in situ component (p = 0.024). Radioguided excision was an independent predictor of complete excision of the invasive component (p = 0.012). Conclusions: Application of radioguided surgery combined with wire localization seems to improve outcome of therapeutic excision of non-palpable invasive breast cancer compared to wire-directed excision alone.

REFERENCES

1. Feig SA. Decreased breast cancer mortality through mammographic screening: results of clinical trials. Radiology 1988;167:659-665.

2. Aitken RJ, Chetty U. Non-palpable mammographic abnormalities. J R Coll Surg Edinb 1991;36:362-371.

3. Cuntz MC, Levine EA, Dorisio TM, et al. Intraoperative gamma detection of 1251-lanreotide in women with primary breast cancer. Ann Surg Oncol 1999;6:367-372.

4. Nieroda CA, Mojzisik C, Sardi A, et al. Staging of carcinoma of the breast using a hand-held gamma detecting probe and nanoclonal antibody B72.3. Surg Gynecol Obstet 1989;169:35-40.

5. Luini A, Zurrida S, Paganelli G, Galimbertu V, et al. Comparison of radioguided excision with wire localization of occult breast lesions. Br J Surg 1999;86:522-525.

6. Gennari R, Galimberti V, de Cicco C, et al. Use of technetium-99m-labeled colloid albumin for preoperative and intraoperative localization of nonpalpable breast lesions. J Am Coll Surg 2000; 190:692-698.

7. Tanis PJ, Duerloo EE, Valdés-Olmos, et al. Single intralesional tracer dose for radioguided excision of clinically occult breast cancer and sentinel node. Ann Surg Oncol 2001; 8:850-855.

8. Gallegos-Hernández JF, Aranda-Soto M, Pichardo P, et al. Linfadenectomía radioguiada del ganglio centinela en cáncer de mama. Cir Ciruj 2002; 70:339-345.

9. Verkooijen HM, Borel RI, Peeters PH, et al. Impact of stereotactic large-core needle biopsy on diagnosis and surgical treatment of non-palpable breast cancer. Eur J Surg Oncol 2001;27:244-249.

10. White RR, Halperin TJ, Olson JA, et al. Impact of core-needle breast biopsy on the surgical management of mammographic abnormalities. Ann Surg 2001;233:769-777.

11. Boerner S, Fornage BD, Singletary E, et al. Ultrasound-guided fine-needle aspiration (FNA) of non-palpable breast lesions: a review of 1885 FNA cases using the National Cancer Institute-supported recommendations on the uniform approach to breast FNA. Cancer 1999;87:19-24.

12. Chadwick DR, Shorthouse AJ. Wire-directed localization biopsy of the breast: an audit of results and analysis of factors influencing therapeutic value in the treatment of breast cancer. Eur J Surg Oncol 1997;23:128-33.

13. Hastrich DJ, Dunn JM, Armstrong JS, et al. Diagnostic and therapeutic aspects of fine-wire localization biopsy for impalpable breast cancer. Br J Surg 1992;79:1038-1041.

14. Allen MJ, Thompson WD, Stuart RC, et al. Management of non-palpable breast lesions detected mammographically. Br J Surg 1994; 81:543-545.

15. Campbell ID, Theaker JM, Royle GT, Coddington R, et al. Impact of an extensive in situ component on the presence of residual disease in screen detected breast cancer. J R Soc Med 1991;84:652-656.

16. Al Sobhi SS, Helvie MA, Pas HA, et al. Extent of lumpectomy for breast cancer alter diagnosis by stereotactic core versus wire-localization biopsy. Ann Surg Oncol 1999;6:330-335.

17. Dixon JM, Ravi SO, Walsh J, Paterson D, et al. Specimen-orientated radiography helps define excision margins of malignant lesions detected by breast screening Br J Surg 1993;80:1001-1002.

18. Chinyama CN, Davies JD, Rayter Z, et al. Factors affecting surgical margin clearance in screen-detected breast cancer and the effect of cavity biopsies on residual disease. Eur J Surg Oncol 1997;23:123-127.

19. Rahusen FD, Taets van Amerongen AH, et al. Ultrasound-guided lumpectomy of nonpalpable breast cancers: a feasibility study looking at the accuracy of obtained margins. J Surg Oncol 1999;72:72-76.

20. Holland R, Hendricks JH, Vebeek AL, et al. Extent, distribution and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet 1990;335:519-522.